

Edgar Filing: CEL SCI CORP - Form NT 10-Q

CEL SCI CORP
Form NT 10-Q
May 16, 2005

U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SEC File Number 0-11503
CUSIP Number 150-837-409

FORM 12b-25

NOTIFICATION OF LATE FILING

(Check One):

Form 10-K Form 20-F Form 11-K Form 10-Q Form N-SAR

For Period Ended: March 31, 2005

Nothing in this Form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: N/A

Part I - Registrant Information

Full Name of Registrant: Cel-Sci Corporation

Former Name if Applicable: N/A

Address of Principal Executive Office (Street and Number)

8229 Boone Blvd. #802

City, State and Zip Code

Vienna, VA 22182

Part II - Rules 12b-25(b) and (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed.
(Check box if appropriate)

(a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

(b) The subject annual report, semi-annual report, or transition report or

Edgar Filing: CEL SCI CORP - Form NT 10-Q

portion thereof will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and

[] (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

Part III - Narrative

State below in reasonable detail the reasons why the Form 10-K, 20-F, 11-K, 10-Q, or N-SAR, or the transition report or portion thereof could not be filed within the prescribed time period.

The Company plans to make an announcement regarding the publication of very important clinical and histopathological data with regards to its Multikine drug. The Company wants to include this announcement under Item 5 of its 10-Q report for the period ended March 31, 2005. Since the Company expects to make this announcement after May 16, 2005 (which is the date the 10-Q report is due) additional time is needed to file the report.

Part IV - Other Information

(1) Name and telephone number of person to contact in regard to this notification

William T. Hart (303) 839-0061
(Name) (Area Code) (Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) been filed? If answer is no, identify report(s). [X] Yes [] No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? [] Yes [X] No

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Cel-Sci Corporation
(Name of Registrant as specified in charter)

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Date: May 16, 2005 By /s/ Geert R. Kersten

Edgar Filing: CEL SCI CORP - Form NT 10-Q

Geert R. Kersten,
Chief Executive Officer
Cel-Sci Corporation
8229 Boone Blvd., # 802
Vienna, VA 22182
(703) 506-9460

ATTENTION

Intentional misstatements or omissions of fact constitute Federal Criminal
Violations (See 18 U.S.C. 1001).